innoVitroinnoVitro has been recognized by GHP (Global Health & Pharma) as most innovative in vitro technology company in Germany for the year 2022. Read the interview with Matthias Gossmann, CEO of innoVitro hereContinue readinginnoVitro awarded as most innovative in vitro technology company in Germany
The article from Chirikian et al., 2022 covering April and May of the innoVation Series addresses the effects of xeno-free cryopreservation on the contractile properties of human iPSC-derived cardiomyocytes. Read the article to find out about alterations in both the contractile and calcium handling properties of xeno-free cryopreserved hiPSC-CMs. Collectively, the authors observed increased force…Continue readinginnoVation Series April – May 2022
Meet us at Maastrichts Expositie en Congres Centrum in September 2022.Continue readingMeet us at the XVIth International Congress of Toxicology (ICT), September 18 – 21, 2022 in Maastricht, Netherlands.
Meet us in Montréal, Canada at the Safety Pharmacology Society Annual Meeting in September 2022.Continue readingSafety Pharmacology Society Annual Meeting, September 11 -14, 2022 in Montréal, Canada.
Check out our poster entitled “Tackling human iPSC-cardiomyocte maturation in vitro for predictive nonclinical cardio-toxicological assessment” at the SOT poster session in collaboration with Nanion Technologies!Continue readingSociety of Toxicology Annual Meeting, San Diego, CA, March 27-31, 2022
In the March issue of the innovation Series a charcterization study of cardiac cells and their gene expression profiles was performed. Six anatomical adult heart regions were analyzed to establish a cardiac cell atlas for better understanding of the adult human heart. In detail, Litviňuková et al., 2022 highlight the cellular heterogeneity of cardiomyocytes, pericytes…Continue readinginnoVation Series – March 2022
A newly published article assessing human induced pluripotent stem cell derived-cardiomyocyte (hiPSC-CM) contractility kinetics caught our interest this month. The data shows that flexible substrates are necessary for normal twitch-like contractility kinetics and interpretation of inotropic interventions. Huethorst et al. analyzed spatiotemporal contractility of hiPSC-CM monolayers seeded on conventional, rigid surfaces (glass or plastic) and…Continue readinginnoVation Series – February 2022
The last part of our innoVation Facts series dealing with cardiac maturation cues focused on gene expression analysis of human iPSC-derived cardiomyocytes (hiPSC-CMs) cultured either on physiological FLEXcyte or regular cell culture plates. The data shows increased expression levels of ACTC1 and ACTN2 genes (both producing cytoskeleton-related proteins) as well as the MYH7 gene (important…Continue readinginnoVation Facts – Cardiac Maturation Cues (Part 3)
We start the new year with an article by Lebrec et al., 2021 covering CAR-T / TCR immunotherapy research findings with a focus on nonclinical safety evaluation. Engineered T cell therapies provide huge opportunities to address current unmet medical needs but present also unique challenges in terms of safety assessment during nonclinical and clinical development.…Continue readinginnoVation Series – Research Article of the Month – January
Meet us at the 66th Biophysical Society Meeting at the Moscone Center in San Francisco, California, USA. We will present new data on how to fascilitate cardiac maturation cues of human iPSC-derived cardiomyocytes for in vitro cardiac risk evaluation at Nanion Technologies exhibitor symposium taking place on Monday, 21st of February, 2022.Continue readingBiophysical Society 66th Annual Meeting, February 19 -23, 2022
